About Atea Pharmaceuticals
Atea Pharmaceuticals is a company based in Boston (United States) founded in 2014 by Jean Pierre Sommadossi. It operates as a Professional Services. Atea Pharmaceuticals has raised $293.43 million across 6 funding rounds from investors including Bain Capital, RA Capital and Perceptive Advisors. The company has 56 employees as of December 31, 2024. Atea Pharmaceuticals offers products and services including Bemnifosbuvir + Ruzasvir and AT-527. Atea Pharmaceuticals operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Boston, United States
- Employees 56 as on 31 Dec, 2024
- Founders Jean Pierre Sommadossi
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Atea Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-168.38 M-23.85as on Dec 31, 2024
-
EBITDA
$-192.53 M-17.58as on Dec 31, 2024
-
Total Equity Funding
$293.43 M (USD)
in 6 rounds
-
Latest Funding Round
-
Investors
Bain Capital
& 11 more
-
Employee Count
56
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Atea Pharmaceuticals
Atea Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AVIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Atea Pharmaceuticals
Atea Pharmaceuticals offers a comprehensive portfolio of products and services, including Bemnifosbuvir + Ruzasvir and AT-527. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Combination therapy developed for treating Hepatitis C virus.
Therapy developed for treatment of COVID-19 patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Atea Pharmaceuticals
Atea Pharmaceuticals has successfully raised a total of $293.43M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Last Round
-
First Round
First Round
(01 May 2014)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Post-IPO - Atea Pharmaceuticals | Valuation | GSA Capital Partners |
|
| May, 2020 | Amount | Series D - Atea Pharmaceuticals | Valuation | Bain Capital | |
| Jul, 2018 | Amount | Series C - Atea Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Atea Pharmaceuticals
Atea Pharmaceuticals has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Bain Capital, RA Capital and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are pursued across multiple sectors.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Atea Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Atea Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Atea Pharmaceuticals Comparisons
Competitors of Atea Pharmaceuticals
Atea Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Atea Pharmaceuticals
Frequently Asked Questions about Atea Pharmaceuticals
When was Atea Pharmaceuticals founded?
Atea Pharmaceuticals was founded in 2014.
Where is Atea Pharmaceuticals located?
Atea Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Atea Pharmaceuticals?
Jean Pierre Sommadossi is the current CEO of Atea Pharmaceuticals. They have also founded this company.
Is Atea Pharmaceuticals a funded company?
Atea Pharmaceuticals is a funded company, having raised a total of $293.43M across 6 funding rounds to date. The company's 1st funding round was a Series C of $27.6M, raised on May 01, 2014.
How many employees does Atea Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Atea Pharmaceuticals is 56.
What does Atea Pharmaceuticals do?
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapies for serious viral diseases. The company is primarily engaged in advancing treatments for Hepatitis C virus (HCV) through its regimen of bemnifosbuvir and ruzasvir, which is in a global Phase 3 development program. Additionally, innovative therapies are being developed to address unmet medical needs in the antiviral sector, including collaborations for COVID-19 treatments. A deep understanding of antiviral drug development, medicinal chemistry, and virology is leveraged to create novel product candidates targeting single-stranded RNA viruses.
Who are the top competitors of Atea Pharmaceuticals?
Atea Pharmaceuticals's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does Atea Pharmaceuticals offer?
Atea Pharmaceuticals offers Bemnifosbuvir + Ruzasvir and AT-527.
Is Atea Pharmaceuticals publicly traded?
Yes, Atea Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AVIR.
Who are Atea Pharmaceuticals's investors?
Atea Pharmaceuticals has 12 investors. Key investors include Bain Capital, RA Capital, Perceptive Advisors, GSA Capital Partners, and Rock Springs Capital.
What is Atea Pharmaceuticals's ticker symbol?
The ticker symbol of Atea Pharmaceuticals is AVIR on NASDAQ.